Volume 6.42 | Oct 27

Hematopoiesis News 6.42 October 27, 2015
Hematopoiesis News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  HN on Twitter
Study Uses Gene Editing to Take Brakes off Lab-Based Red Blood Cell Production
Researchers wanted to see if it were possible to use SH2B3 as a target to genetically increase the yield of laboratory-based red blood cell production processes. They confirmed that shutting off SH2B3 with RNAi skews a hematopoietic stem and progenitor cell’s profile of cell production to favor red blood cells. [Press release from Dana-Farber Cancer Institute discussing online prepublication in Cell Stem Cell]
Press Release | Abstract | Graphical Abstract
UM171 & UM729 - Get the Authentic Small Molecules for Ex Vivo Expansion of Human HSCs
PUBLICATIONS (Ranked by impact factor of the journal)
Leukemia-Associated Cohesin Mutants Dominantly Enforce Stem Cell Programs and Impair Human Hematopoietic Progenitor Differentiation
Scientists showed that mutant cohesin proteins block differentiation of human hematopoietic stem and progenitor cells in vitro and in vivo and enforce stem cell programs. [Cell Stem Cell]
Abstract | Graphical Abstract

JMJD1C Is Required for the Survival of Acute Myeloid Leukemia by Functioning as a Coactivator for Key Transcription Factors
Scientists demonstrated that the histone demethylase JMJD1C functions as a coactivator for RUNX1–RUNX1T1 and is required for its transcriptional program. [Genes Dev] Abstract | Press Release

Agonist Antibody That Induces Human Malignant Cells to Kill One Another
Recently, investigators discovered a phenomenon that they call “receptor pleiotropism” in which agonist antibodies against known receptors induce cell fates that are very different from those induced by the natural agonist to the same receptor. Here, they showed that one can take advantage of this phenomenon to convert acute myeloblastic leukemic cells into natural killer cells. [Proc Natl Acad Sci USA] Abstract | Press Release

Phenotypic, Morphological and Adhesive Differences of Human Hematopoietic Progenitor Cells Cultured on Murine versus Human Mesenchymal Stromal Cells
Researchers evaluated the proliferative capacity, morphological and physical characteristics of human CD34+ hematopoietic stem and progenitor cells after co-culture on murine or human bone marrow-derived mesenchymal stromal cells. [Sci Rep] Full Article

SKLB-677, an FLT3 and Wnt/β-Catenin Signaling Inhibitor, Displays Potent Activity in Models of FLT3-Driven AML
Scientists report the characterization of SKLB-677, a new FLT3 inhibitor developed recently. This compound showed considerable suppression effects on leukemia stem-like cells in in vitro functional assays, but had no influence on normal hematopoietic stem cells. [Sci Rep] Full Article

Induced Developmental Arrest of Early Hematopoietic Progenitors Leads to the Generation of Leukocyte Stem Cells
Scientists showed that a simple block of cell differentiation is sufficient to induce and maintain stem cells. By overexpression of the transcriptional inhibitor ID3 in murine hematopoietic progenitor cells and cultivation under B cell induction conditions, the cells underwent developmental arrest and enter a self-renewal cycle. [Stem Cell Reports] Full Article | Graphical Abstract | Press Release

Three-Dimensional Microfluidic Tri-Culture Model of the Bone Marrow Microenvironment for Study of Acute Lymphoblastic Leukemia
To study acute lymphoblastic leukemia in a model of in vivo relevance, the authors engineered a 3-D microfluidic cell culture platform. They showed decreased chemotherapeutic drug sensitivity of leukemic cells in 3-D tri-culture models from the 2-D models. [PLoS One] Full Article


Sirolimus Is Effective in Relapsed/Refractory Autoimmune Cytopenias: Results of a Prospective Multi-Institutional Trial
Scientists present data on 30 patients treated on a multicenter prospective clinical trial using sirolimus as monotherapy. [Blood] Abstract | Press Release

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Biphenotypic Acute Leukemia
The authors retrospectively analyzed the outcomes of hematopoietic cell transplantation in biphenotypic acute leukemia patients in Japan in comparison to acute myeloid leukemia and acute lymphoblastic leukemia using the registration data from a nationwide database. [Ann Hematol] Abstract

Improved Outcomes of Hematopoietic Stem Cell Transplantation in Patients with Infantile Malignant Osteopetrosis Using Fludarabine-Based Conditioning
Investigators present their experience with hematopoietic stem cell transplantation for infantile malignant osteopetrosis patients comparing different types of conditioning regimens. [Pediatr Blood Cancer] Abstract

Learn more about T cell activation and expansion with ImmunoCult™
The Role of EVI-1 in Normal Hematopoiesis and Myeloid Malignancies
The authors focus on the biochemical properties of ecotropic virus integration site-1 (EVI-1) which plays a role in myeloid malignancies. [Int J Oncol] Abstract

Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.
BioSight Will Present Interim Results From a Phase I/II Clinical Trial of Astarabine for Treating Acute Leukemia at the ASH Annual Meeting 2015
BioSight Ltd. announced it shall report interim results from an ongoing Phase I/IIa clinical study of Astarabine™ in leukemia patients. [Press release from BioSight Ltd. (PR Newswire LLC.) discussing research to be presented at the 57th American Society of Hematology (ASH) Annual Meeting, Orlando] Press Release

From our sponsor:
Quickly find the whole-blood frequencies of human and mouse immune cell types.
Download the app.
Ley Receives $6.4 Million NCI Award for Leukemia Research​​
Timothy J. Ley, MD, a leukemia researcher and hematologist at Washington University School of Medicine in St. Louis, has received a seven-year, $6.4 million Outstanding Investigator Award from the National Cancer Institute (NCI) of the National Institutes of Health. [Washington University in St. Louis] Press Release

New Anticancer Drug Discovery Company
A new company, Femtogenix Ltd, has been formed by King’s College London and Research Corporation Technologies. The main aim of Femtogenix is to develop a new generation of very potent molecules—known as ‘payloads’—that can be attached to targeting systems and then used as a form of highly specific chemotherapy to kill cancer cells with greatly reduced side effects. [King’s College London] Press Release
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Cell Culture 2016
February 2-4, 2016
London, United Kingdom

Visit our events page to see a complete list of events in the hematopoiesis community.
NEW Postdoctoral Position – Stem Cells and Leukemia (Florida State University)

NEW PhD Studentships – Cancer Research (Cancer Research UK Manchester Institute)

Principal Scientist – Hematopoietic Products (STEMCELL Technologies Inc.)

Assistant or Associate Professor – Cell and Regenerative Biology (University of Wisconsin, Madison)

Postdoctoral Research Fellow – Medicinal Chemistry for Cancer Drug Discovery (University of Michigan)

Research Technician – Stem Cell and Gene Therapy (Fred Hutchinson Cancer Research Center)

Postdoctoral Fellow – iPSC Models of Hematologic Disorders (Icahn School of Medicine at Mount Sinai)

Postdoctoral Fellow – Leukemia Stem Cell Biology (Lund University)

Postdoctoral Fellow – Leukemia, Stem Cells and Development (Josep Carreras Leukemia Research Institute)

Postdoctoral Positions – Cancer and Developmental Biology (North Carolina Central University)

Assistant Professor – Stem Cell Biology (University of South Carolina)

Postdoctoral Position – Hematology and Immunology (University of Liege)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Hematopoiesis News: Archives | Events | Contact Us